Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "China-Pharma"

3 News Found

China Pharma submits plan of compliance to NYSE American
News | July 18, 2022

China Pharma submits plan of compliance to NYSE American

The company was directed to submit a plan of compliance by July 15, 2022

Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Drug Approval | November 16, 2023

Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer

Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient

CPHI & PMEC China 2023 to see surge from pent up international ingredients demand
News | May 03, 2023

CPHI & PMEC China 2023 to see surge from pent up international ingredients demand

China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey

Latest Stories

Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging